Program
XTR003
A development code. Also written as “Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging”.
Its studies are mostly in Heart Failure · Myocardial Ischemia · Coronary Artery Disease, led by Sinotau Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinotau Pharmaceutical Group | 31 open or running | phase 2since Dec 25, 2022 | Nov 23, 2021 | Dec 31, 2026phase 2 · NCT07443696 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 23, 2021First study: phase 1 study in Coronary Artery DiseaseFirst studyNCT05136391 · 10 enrolled · China
- Dec 25, 2022Phase 2 study in Myocardial IschemiaNCT05885854 · 51 enrolled · China
- Dec 24, 2025Phase 2 study in Heart FailureNCT07443696 · 40 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Heart FailureNCT07443696
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07443696Heart Failure · China | 2 | Recruiting | Dec 31, 2026 | 40 |
| NCT05885854Myocardial Ischemia · China | 2 | Completed | Mar 4, 2023 | 51 |
| NCT05136391Coronary Artery Disease · China | 1 | Completed | Aug 27, 2021 | 10 |
How it is read
Names in the registry
- “XTR003”, 2 entries
- “Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging”, 1 entry
Codes read as this program: XTR003.
Conditions, from the studies’ own filings
- Heart Failure, 1 study
- Myocardial Ischemia, 1 study
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.